Holen Sie sich die Stockscreener-App
6.97
0.43%
0.03
Vorhandelsmarkt:
6.81
-0.16
-2.30%
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
UNCY Options Volatility — NASDAQ:UNCY - TradingView — Track All Markets
UNCY Options Chain — NASDAQ:UNCY - TradingView — Track All Markets
Equities Analysts Offer Predictions for UNCY Q1 Earnings - National Today
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. t - GuruFocus
Unicycive Therapeutics to Present at Annual Healthcare Conference - National Today
Unicycive CEO to Present at Needham Conference - National Today
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - PR Newswire
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Brookline Capital Markets Estimates UNCY Q2 Earnings - MarketBeat
Market Leaders: Should you avoid Unicycive Therapeutics Inc stock right now2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Growth Recap: What is the earnings history of Unicycive Therapeutics IncTreasury Yields & Real-Time Market Sentiment Reports - baoquankhu1.vn
Brookline Capital cuts Unicycive stock price target on share count By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
UNCY Stock Price, Quote & Chart | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Benchmark cuts Unicycive Therapeutics price target on updated assumptions By Investing.com - Investing.com Canada
Unicycive Therapeutics director Gaurav Aggarwal resigns from board - Investing.com UK
Unicycive Therapeutics director Gaurav Aggarwal resigns from board By Investing.com - Investing.com India
Unicycive Therapeutics, Inc. Files Form 8-K Announcing Departure and Appointment of Directors and Officers - Minichart
Unicycive Therapeutics (UNCY) director Gaurav Aggarwal steps down from board - Stock Titan
Unicycive Therapeutics | 8-K: Current report - Moomoo
Gaurav Aggarwal resigns from Unicycive Board - TradingView — Track All Markets
Unicycive Therapeutics, Inc. Announces Resignation of Gaurav Aggarwal from the Board of Directors, Effective April 6, 2026 - marketscreener.com
Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00 - MarketBeat
Aug Movers: Should you avoid Unicycive Therapeutics Inc stock right now2026 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
HC Wainwright Boosts Earnings Outlook for Unicycive Therapeutics - National Today
HC Wainwright Issues Positive Estimate for UNCY Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Unicycive Therapeutics (UNCY) Target Price Lowered by Guggenheim | UNCY Stock News - GuruFocus
Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - MarketBeat
Noble Financial Has Positive Forecast for UNCY Q1 Earnings - MarketBeat
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - stocktwits.com
UNCY SEC FilingsUnicycive Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Noble Financial Brokers Boost Earnings Estimates for UNCY - MarketBeat
H.C. Wainwright reiterates Unicycive stock rating, $22 target By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Noble Financial Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Unicycive Therapeutics | 10-K: FY2025 Annual Report - Moomoo
Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings - AlphaStreet
USA Rare Earth, Inc. (USAR) Reports Q4 Earnings - AlphaStreet
Unicycive Therapeutics Reports 2025 Financial Results; OLC NDA Under FDA Review with Potential Approval in June 2026 - Minichart
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - National Today
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS - MarketBeat
Unicycive (UNCY) narrows 2025 loss, FDA accepts kidney drug NDA resubmission - Stock Titan
Unicycive Therapeutics : March 2026 Corporate Presentation - marketscreener.com
Unicycive Therapeutics 10-K: Net loss $26.6M, EPS $(1.67) - TradingView
Unicycive (NASDAQ: UNCY) advances OLC NDA toward June 2026 PDUFA as UNI-494 is paused - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Published on: 2026-03-28 07:58:35 - baoquankhu1.vn
Published on: 2026-03-27 21:20:10 - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) Stock Analysis Report | Financials & Insights - Benzinga Japan
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):